17:03:06 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Zealand Pharma är verksamma inom bioteknik. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg.

Kalender

2022-11-10 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-05-09 Ordinarie utdelning ZEAL 0.00 DKK
2022-04-06 Årsstämma 2022
2022-03-10 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-04-16 Ordinarie utdelning ZEAL 0.00 DKK
2021-04-15 Årsstämma 2021
2021-03-11 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-03 Ordinarie utdelning ZEAL 0.00 DKK
2020-04-02 Årsstämma 2020
2020-03-12 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Kvartalsrapport 2019-Q1
2019-04-05 Ordinarie utdelning ZEAL 0.00 DKK
2019-04-04 Årsstämma 2019
2019-03-07 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-16 Kvartalsrapport 2018-Q1
2018-04-20 Ordinarie utdelning ZEAL 0.00 DKK
2018-04-19 Årsstämma 2018
2018-03-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-17 Kvartalsrapport 2017-Q1
2017-04-06 Ordinarie utdelning ZEAL 0.00 DKK
2017-04-05 Årsstämma 2017
2017-03-15 Bokslutskommuniké 2016
2016-11-09 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 Kvartalsrapport 2016-Q1
2016-04-20 Ordinarie utdelning ZEAL 0.00 DKK
2016-04-19 Årsstämma 2016
2016-03-16 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-22 Kvartalsrapport 2015-Q1
2015-04-22 Ordinarie utdelning ZEAL 0.00 DKK
2015-04-21 Årsstämma 2015
2015-03-12 Bokslutskommuniké 2014
2014-03-21 Ordinarie utdelning ZEAL 0.00 DKK
2013-04-30 Ordinarie utdelning ZEAL 0.00 DKK
2012-04-26 Ordinarie utdelning ZEAL 0.00 DKK
2012-04-25 Årsstämma 2012
2011-04-29 Ordinarie utdelning
2021-11-30 17:00:00

Company announcement – No. 72 / 2021

Total number of shares and voting rights in Zealand Pharma at November 30, 2021

Copenhagen, DK and Boston, MA, November 30, 2021 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.  

In Company announcement No. 69/2021 from November 19, 2021, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including November 30, 2021.



Date
Number of shares
(nominal value of DKK 1 each)
Share capital
(nominal value in DKK)
Number of voting rights
November 30, 202143,628,74243,628,74243,628,742

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunity for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

Zegalogue® and V-Go® are registered trademarks of Zealand Pharma A/S.

Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com 
 
Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com